These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 13705073)

  • 21. Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization.
    REILLY CM; STOKES J; BUYNAK EB; GOLDNER H; HILLEMAN MR
    N Engl J Med; 1961 Jul; 265():165-9. PubMed ID: 13740532
    [No Abstract]   [Full Text] [Related]  

  • 22. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic.
    Guerbois M; Moris A; Combredet C; Najburg V; Ruffié C; Février M; Cayet N; Brandler S; Schwartz O; Tangy F
    Virology; 2009 May; 388(1):191-203. PubMed ID: 19345390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines.
    Bellanti JA; Sanga RL; Klutinis B; Brandt B; Artenstein MS
    N Engl J Med; 1969 Mar; 280(12):628-33. PubMed ID: 4179401
    [No Abstract]   [Full Text] [Related]  

  • 24. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
    Just M; Berger R; Glück R; Wegmann A
    Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of live attenuated measles and mumps vaccines in children with acute leukemia.
    Torigoe S; Hirai S; Oitani K; Ito M; Ihara T; Iwasa T; Kamiya H; Sakurai M; Ueda S; Yamanishi K
    Biken J; 1981 Dec; 24(4):147-51. PubMed ID: 7346040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potency control of live, attenuated vaccines against measles used in children vaccinations in the State of São Paulo, Brazil [1976-1980].
    Pral MM; Woe Fang FL; de Rizzo E
    Rev Inst Med Trop Sao Paulo; 1982; 24(1):1-5. PubMed ID: 7123066
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
    Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
    Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on further attenuated live measles vaccine. IV. Clinical and serological evaluation of a clone of CAM-CEF measles vaccine virus.
    Ueda S; Takahashi M; Kurimura T; Ogino T; Suzuki N
    Biken J; 1970 Sep; 13(3):169-74. PubMed ID: 5530511
    [No Abstract]   [Full Text] [Related]  

  • 29. Studies on further attenuated live measles vaccine. 3. Selection of less reactive variants of CAM measles vaccine virus.
    Takaku K; Sasada T; Konobe T; Onishi K; Ueda S
    Biken J; 1970 Sep; 13(3):163-8. PubMed ID: 5530510
    [No Abstract]   [Full Text] [Related]  

  • 30. [Measles vaccination with split vaccines and living vaccines (author's transl)].
    Stehr K; Enders-Ruckle G; Spiess H
    MMW Munch Med Wochenschr; 1975 Jul; 117(27):1159-64. PubMed ID: 808710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on further attenuated live measles vaccine. V. Immunization test of CAM-A4 measles vaccine on handicapped children.
    Ueda S; Okuno Y; Sakamoto Y
    Biken J; 1970 Sep; 13(3):175-8. PubMed ID: 4249672
    [No Abstract]   [Full Text] [Related]  

  • 32. Measles susceptibility in two Pacific atoll populations. Epidemiological factors and response to live attenuated measles virus.
    Willis MF; Warburton MF
    Med J Aust; 1974 May; 1(20):789-93. PubMed ID: 4853112
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of extremely attenuated live measles virus vaccine (CAM-EX).
    Ueda S; Takahashi M; Kurimura T; Minekawa Y; Suzuki N
    Biken J; 1972 Sep; 15(3):173-7. PubMed ID: 4643692
    [No Abstract]   [Full Text] [Related]  

  • 34. Persistence of immunity against measles in persons immunized with Edmonston-Zagreb vaccine.
    abu Eldan J; Borćić B; Smerdel S
    Acta Med Croatica; 1991; 45(4-5):297-304. PubMed ID: 1726513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles immunity after revaccination: results in children vaccinated before 10 months of age.
    Linnemann CC; Dine MS; Roselle GA; Askey PA
    Pediatrics; 1982 Mar; 69(3):332-5. PubMed ID: 7063289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and immunological response to live tissue culture vaccine against measles.
    SMORODINTSEV AA; BOICHUK LM; SHIKINA ES; BATANOVA TB; BYSTRYAKOVA LV; PERADZE TV
    Acta Virol; 1960 Jul; 4():201-4. PubMed ID: 13854875
    [No Abstract]   [Full Text] [Related]  

  • 37. Electroencephalographic studies on children having measles with no clinical evidence of involvement of the central nervous system.
    GIBBS EL; GROSSMAN HJ; SPIES HW
    Pediatrics; 1956 Oct; 18(4):556-60. PubMed ID: 13370223
    [No Abstract]   [Full Text] [Related]  

  • 38. The electroencephalographic findings in measles encephalitis.
    MARSH C
    Bull Los Angel Neuro Soc; 1948 Mar; 13(1):15-8. PubMed ID: 18910042
    [No Abstract]   [Full Text] [Related]  

  • 39. Measles encephalitis; clinical and electroencephalographic study.
    SPRAGINS M; SHINNERS BM; ROCHESTER B
    Pediatrics; 1950 Apr; 5(4):599-616. PubMed ID: 15417261
    [No Abstract]   [Full Text] [Related]  

  • 40. Electroencephalographic findings in measles encephalitis.
    HODES HL; LIVINGSTON S
    J Pediatr; 1950 May; 36(5):577-82. PubMed ID: 15415834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.